|Slideshows|January 8, 2020

Psychiatric Sequelae of Pandemics

Psychiatrists are likely to encounter patients with depression, anxiety, and paranoia related to communicable diseases and pandemics. Following is a summary of memorable epidemics/pandemics.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

When Brain Injury and Mental Health Look the Same: The Diagnostic Challenge of Concussion Recovery

ByBrandee Grate-Perry, MSW, LCSWA,Mena Mirhom, MD, FAPA

July 27th 2026

Positive Phase 3 Data for Centanafadine to Treat Comorbid ADHD and Anxiety

ByJessica Walters

July 1st 2026

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

ByMark Gerstein, PhD

June 5th 2026

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

ByLeah Kuntz

May 20th 2026

The Clinical Uses and Importance of Lifestyle Medicine in Psychiatry

ByFarah Abbas, BS,Asim A. Shah, MD

April 29th 2026

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Psychiatric Sequelae of Pandemics

Related Content

When Brain Injury and Mental Health Look the Same: The Diagnostic Challenge of Concussion Recovery

Positive Phase 3 Data for Centanafadine to Treat Comorbid ADHD and Anxiety

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

The Clinical Uses and Importance of Lifestyle Medicine in Psychiatry

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD